Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
So-Young International (SY): Assessing the +270% Path to the $7.30 Analyst Target

So-Young International (SY): Assessing the +270% Path to the $7.30 Analyst Target

Key Takeaways

  • The central $7.30 stock price target is the arithmetic mean of two verified 12-month analyst price targets, rounded from an underlying mean near $7.30.
  • At a recent price near $1.97, reaching $7.30 would require a gain of roughly 270%, a very large move even by small-cap standards.
  • The two published targets span a wide range from approximately $4.80 to $9.80, reflecting sharply different assumptions about a profitability turnaround.
  • Supporting factors include a rapid pivot into branded aesthetic centers, forecast revenue growth above 30%, and a heavily depressed valuation.
  • The biggest risks are persistent losses, China's weak consumer environment, regulatory pressure on medical aesthetics, and the company's thin analyst coverage.
  • For more detail on this ticker, explore Major News, Today's Price Move, the Forecast page, and Earnings coverage.
  • Readers can also explore Trending AI Robots to see how algorithmic strategies are scanning the market for opportunities.

Analyst Price Targets and Consensus View

Coverage of SY is unusually thin. According to data from S&P Global aggregated by StockAnalysis, only two analysts currently publish 12-month price targets, producing an average near $7.34 with a low near $5.03 and a high near $9.65. Other aggregators report a comparable mean of roughly $7.29, with a low-to-high band around $4.80 to $9.80. Averaging the valid targets and rounding yields the $7.30 central figure used here.

Covering firms include Canaccord Genuity and Citic Securities, while Citi's Nelson Cheung upgraded the stock to Buy in mid-2025 with a target that has since been revised. The gap between the lowest and highest targets is enormous, which signals deep disagreement rather than a confident consensus. Aggregators label the rating anywhere from "Strong Buy" to "Hold," reflecting the split between a turnaround thesis and skepticism about the company's losses. This mean should be read as a rough anchor, not a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

With the stock near $1.97, a rise to $7.30 represents upside of about 270%, which is a very large required move. The 52-week range runs from roughly $1.28 to about $3.90, so even recovering to the prior high would still leave the shares far below the central target.

A path toward the target would require more than a technical bounce. So-Young has been pivoting from its legacy information and reservation services into direct aesthetic treatment centers and equipment sales through its Wuhan Miracle segment. That shift has driven strong segment growth, but it has also compressed gross margins and kept the company loss-making. Consensus estimates point to revenue growth of roughly 35% for fiscal 2026 and continued earnings per share (EPS) losses, meaning the stock would need a substantial re-rating of its valuation multiple, not just top-line improvement.

What Could Support a Move Toward the Target

  • The aesthetic treatment center business grew rapidly, reportedly around 186% year over year in early 2026, and now represents a large share of revenue.
  • Consensus forecasts call for revenue to rise from about RMB1.52 billion in 2025 toward RMB2.05 billion in 2026 and RMB2.79 billion in 2027.
  • The shares trade at a price-to-sales (P/S) ratio well below one, leaving room for multiple expansion if profitability improves.
  • Share buybacks and lower impairment charges in recent quarters could support per-share value.

What Could Prevent the Target From Being Reached

  • The company remains unprofitable, and EPS estimates are still negative for 2026 and 2027, which keeps the valuation debate unresolved.
  • China's soft consumer confidence and regulatory scrutiny of medical aesthetics advertising and services have historically weighed on demand.
  • The mix shift toward lower-margin product sales and clinic operations has pressured gross margins.
  • Executive turnover, including a 2025 chief financial officer resignation and a new CFO appointment in 2026, adds execution uncertainty.
  • Extremely thin coverage means any single analyst revision can swing the apparent "consensus" dramatically.

Technical Levels and Market Structure

The 52-week low near $1.28 is the most important downside support level, while the prior highs around $3.90 to $4.75 form the first meaningful resistance zones. The $2.00 mark is a psychological level that the stock has struggled around. A sustained move above $5.00 would be needed to even begin challenging a target near $7.30, and no durable technical structure currently supports that scenario.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though the two firms covering SY do not publish identical timelines. Investors should watch quarterly earnings and guidance, particularly the growth and profitability of the aesthetic center segment; any analyst target revisions, given how few there are; China's consumer and regulatory environment; and the company's progress toward breakeven. The next earnings report was expected around late November 2026.

Exploring AI-Driven Signals

In my own analysis process, I find Tickeron's AI Daily Buy/Sell Signals helpful for gaining an extra layer of insight on thinly covered names. The tool applies artificial intelligence to scan market conditions and technical patterns across thousands of stocks, which can complement fundamental work on volatile micro-caps like this one. It has become a regular part of how I cross-check ideas before forming a fuller view.

Final Assessment

The $7.30 central target is the mean of just two analyst price targets spanning roughly $4.80 to $9.80, a range so wide that it reflects fundamentally different views of whether So-Young can turn its fast-growing but loss-making clinic and equipment businesses into durable profits. Reaching the target would require a gain of about 270% from current levels, a very large move that depends on accelerating revenue, a return to profitability, and a significant re-rating of the valuation. The strongest supports are the company's growth pivot and its depressed multiple, while the principal obstacles are persistent losses, China's macro and regulatory backdrop, and minimal analyst coverage. Neither the target nor the wide-ranging analyst views should be treated as a forecast, and the outcome remains highly uncertain.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SY

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


SY's RSI Indicator recovers from oversold territory

The RSI Oscillator for SY moved out of oversold territory on November 10, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In 41 of the 46 cases the stock moved higher. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for SY just turned positive on November 06, 2026. Looking at past instances where SY's MACD turned positive, the stock continued to rise in 25 of 38 cases over the following month. The odds of a continued upward trend are 66%.

Following a +6.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where SY advanced for three days, in 221 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

SY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SY as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

SY moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SY crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

The 50-day moving average for SY moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for SY entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.141) is normal, around the industry mean (4.523). P/E Ratio (-0.846) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.430) is also within normal values, averaging (1.536). SY has a moderately high Dividend Yield (0.052) as compared to the industry average of (0.011). P/S Ratio (1.067) is also within normal values, averaging (6.105).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. SY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -8%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 11%. CARL experienced the highest price growth at 21%, while DRIO experienced the biggest fall at -52%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was -6% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 53
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -3 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of online information and reservation services related to medical aesthetics

Industry ServicestotheHealthIndustry

Industry
Internet Software Or Services
Address
No. 66 Xiangbin Road
Phone
+86 1087902012
Employees
2348
Web
https://www.soyoung.com
Interact to see
Advertisement
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.